检索结果-南通市图书馆

Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2023年第10期8卷 4978-4984页

作者： Weiping Liu ningjing lin Xinqin Feng Yan Xie Chong You Xiaohua Zhou Yuqin Song Jun Zhu Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education) Department of LymphomaPeking University Cancer Hospital&InstituteBeijing 100142China school of Mathematical Sciences Peking UniversityBeijing 100871China Beijing International Center for Mathematical Research Peking UniversityBeijing 100871China Department of Biostatistics School of Public HealthPeking UniversityBeijing 100871China

Anti-programmed cell death-1(anti-PD-1)therapies have shown a favorable efficacy and good tolerance for relapsed or refractory(r/r)classical Hodgkin lymphoma(cHL).However,there are limited data on long-term outcomes among patients with r/r cHL who achieve an objective response to anti-PD-1 therapies.A total of 260 responders from four,phase 2 clinical trials were included in this *** median age was 32 years with a male/female ratio of 1.3:*** a median follow-up period of 31.1 months,116(44.6%)responders experienced disease progression and 18(6.9%)died.

关键词： patients lymphoma relapse

Primary gastrointestinal mantle lymphoma with massive bleeding: a case report and literature review

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2013年第2期25卷 250-253页

作者： Wen Zheng Yuqin Song ningjing lin Meifeng Tu Weiping Liu Jun Zhu Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) Department of Lymphoma Peking University Cancer Hospital & Institute

The incidence of primary gastrointestinal lymphomas （PGILs） has been increasing. The clinical presentation and treatment of PGIL are distinct from those of nodular lymphomas. Symptoms include abdominal pain, abdominal mass, changes in bowel habits, obstruction, and bleeding. Less life- threatening gastrointestinal bleeding occurs after chemotherapy and few reports have focused on the bleeding of PGILs. We report a case of severe gastrointestinal bleeding caused by low-dose chemotherapy, which was dramatically improved by rituximab monotherapy treatment. The prevention and treatment of gastrointestinal bleeding in PGIL should be given much attention.

关键词： Gastrointestinal tract mantle lymphoma bleeding

Prognostic value of pre-and post-transplantation 18F-fluorodeoxyglucose positron emission tomography results in non-Hodgkin lymphoma patients receiving autologous stem cell transplantation

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2017年第6期29卷 561-571页

作者： Zhitao Ying Lan Mi Xuejuan Wang Yuewei Zhang Zhi Yang Yuqin Song Xiaopei Wang WenZheng ningjing lin Meifeng Tu Yan Xie lingyan Ping Chen Zhang Weiping Liu LijuanDeng Jun Zhu Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of LymphomaPeking University Cancer Hospital&InstituteBeijing 100142China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Peking University Cancer Hospital&InstituteBeijing 100142China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of Nuclear MedicinePeking University Cancer Hospital&InstituteBeijing 100142China

Objective： High-dose chemotherapy （HDC） followed by autologous stem cell transplantation （ASCT） is the standard of care in the upfront or relapsed/refractory setting in some patients with non-Hodgkin lymphoma （NHL）. However, a proportion of patients do not respond to ASCT. lSF-fluorodeoxyglueose （FDG） positron emission tomography （PET）/computed tomography （CT） has been widely used for staging, response evaluation, and prognosis prediction. Here, we investigated the prognostic role of PET/CT in NHL patients before and after ASCT. Methods： A retrospective study was conducted at Peking University Cancer Hospital. All NHL patients who underwent ASCT between March 2010 and July 2016 were identified. Patients who had PET/CT scan before and after ASCT were included. Deauville criteria （5-point scale） were used to interpret PET scans. Univariate and multivariate survival analyses were performed using Cox regression. The predictive value of PET scanning was estimated by comparing the area under the receiver operating characteristic （ROC） curve. Results： In total, 79 patients were enrolled in this study. In univariate analysis, pre- and post-ASCT PET result was identified as prognostic factors for 3-year progression-free survival （PFS） and overall survival （OS）. Patients with negative pre-ASCT PET result demonstrated significantly better PFS （84.2% vs. 54.2%） and OS （89.2% vs. 63.6%） than patients with positive pre-ASCT PET result. PFS （91.6% vs. 25.3%） and OS （96.5% vs. 36.8%） were also significantly different between patients with negative and positive post-ASCT PET result. Multivariate analysis also showed a significant association between survival and post-ASCT PET result. ROC analysis revealed that the predictive value of post-ASCT PET result was superior to that of pre-ASCT PET result alone. Combined pre- and post-ASCT PET result is better for predicting outcomes in patients with NHL receiving transplantation. Deauville criteria score 〉3 was identified as the best cutof

关键词： 18F-fluorodeoxyglucose positron emission tomography computed tomography autologous stem celltransplantation high-dose chemotherapy non-Hodgkin lymphoma

Prognostic value of ^(18)F-fluorodeoxyglucose positron emission tomography using Deauville criteria in diffuse large B cell lymphoma treated with autologous hematopoietic stem cell transplantation

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2019年第1期31卷 162-170页

作者： Zhitao Ying Lan Mi Nina Zhou Xuejuan Wang Zhi Yang Yuqin Song Xiaopei Wang Wen Zheng ningjing lin Meifeng Tu Yan Xie lingyan Ping Chen Zhang Weiping Liu Lijuan Deng Jun Zhu Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of LymphomaPeking University Cancer Hospital&InstituteBeijing 100142China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Peking University Cancer Hospital&InstituteBeijing 100142China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of Nuclear MedicinePeking University Cancer Hospital&InstituteBeijing 100142China

Objective: High-dose chemotherapy(HDC) followed by autologous hematopoietic stem cell transplantation(auto-HSCT) plays an important role in improving outcomes of diffuse large B cell lymphoma(DLBCL) patients.18 F-fluorodeoxyglucose(18 F-FDG) positron emission tomography(PET)/computed tomography(CT) has been widely accepted in response assessment and prediction of prognosis in DLBCL. Here, we report the value of 18 FFDG PET/CT pre-and post-HSCT in predicting outcomes of patients with ***: DLBCL patients who had PET/CT scan before and after HSCT were included. PET results were interpreted based upon Deauville criteria. The prognostic value of 18 F-FDG PET/CT in auto-HSCT was ***: Eighty-four patients were enrolled. In univariate analysis, pre-and post-HSCT PET findings were correlated with 3-year progression-free survival(PFS) [hazard ratio(HR)=4.391, P=0.001; HR=7.607, Pline treatment had better outcomes than relapsed/refractory DLBCL patients(3-year PFS, Plinical response to chemotherapy before auto-HSCT and outcomes of patients in the entire cohort(3-year PFS, P<0.001;3-year OS, P<0.001) and in the subgroup of 21 patients with positive pre-HSCT PET(3-year PFS, P=0.084; 3-year OS, P=0.240). A significant association between survival and post-HSCT PET findings was observed in multivariate analysis(HR=5.168, P<0.001).Conclusions: PET results before and after HSCT are useful prognostic factors for DLBCL patients receiving HSCT. Patients who responded to chemotherapy, even those with positive pre-HSCT PET, are appropriate candidates for auto-HSCT.

关键词： Positron emission tomography computed tomography autologous hematopoietic stem cell transplantation high-dose chemotherapy diffuse large B cell lymphoma

PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2017年第1期29卷 66-74页

作者： Wen Zheng Hanyun Ren Xiaoyan Ke Mei Xue Yongqing Zhang Yan Xie ningjing lin Meifeng Tu Weiping Liu lingyan Ping Zhitao Ying Chen Zhang Lijuan Deng Xiaopei Wang Yuqin Song Jun Zhu Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing) Department of Lymphoma Peking University Cancer Hospital & Institute Department of Hematology Peking University First Hospital Department of Hematology Peking University Third Hospital Department of Hematology Air Force General Hospital of Chinese People’s Liberation Army Department of Hematology the 309th Hospital of Chinese People’s Liberation Army

Objective： Although L-asparaginase（L-ASP） is a standard treatment for lymphoblastic lymphoma（LBL）,hypersensitivity reactions by some patients limit its application. Polyethylene glycol-conjugated asparaginase（PEGASP） has a lower immunogenicity and is a standard treatment in all pediatric acute lymphoblastic leukemia（ALL）.In this study, we investigated the efficacy and toxicity of PEG-ASP instead of L-ASP as used in the BFM-90regimen（PEG-ASP-BFM-90） for adult ***： Between June 2012 and July 2015, we treated 30 adult patients with newly diagnosed LBL, using PEGASP-BFM-90 in a prospective, multicenter and single-arm clinical study at 5 participating institutions in ***： All the 30 patients, including 19 males and 11 females with a median age of 30（range： 18–62） years,completed 128 times of the PEG-ASP, with the median of 4（range： 2–6） times. Patients did not receive radiotherapy at this time. The overall response rate was 86.7%（26/30）, with 50.0%（15/30） complete response and36.7%（11/30） partial response. The 3-year overall survival was 46.0% [95% confidence interval（95% CI）,28.2%–64.8%], and the 3-year progression-free survival was 43.0%（95% CI, 25.7%–62.0%）. Major adverse events were myelosuppression, reduced fibrinogen, liver dysfunction and digestive tract toxicities. No allergic reaction and no treatment-related mortality or severe complications were ***： Our clinical data and observed outcomes indicate that 1 dose of PEG-ASP can replace multiple doses of native L-ASP in BFM-90, with predominantly grade 3–4 neutropenia for adult LBL, and no therapyrelated deaths. The effect is similar to previous reports of PEG-ASP-containing regimens for adult ALL. Major advantages include less serious allergic reactions, 2–3 weeks of action duration, and convenience for patients and physicians.

关键词： PEG-asparaginase lymphoblastic lymphoma treatment

A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2022年第1期34卷 53-62页

作者： Zhitao Ying Ting He Shanzhao Jin Xiaopei Wang Wen Zheng ningjing lin Meifeng Tu Yan Xie lingyan Ping Weiping Liu Lijuan Deng Yanping Ding Xuelian Hu Bing Bu Xin’an Lu Yuqin Song Jun Zhu Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of LymphomaPeking University Cancer Hospital&InstituteBeijing 100042China Beijing Immunochina Pharmaceuticals Co. Ltd.Beijing 100195China Department of Medical Oncology Shandong Cancer Hospital and InstituteShandong First Medical University and Shandong Academy of Medical SciencesJinan 250117China

Objective:Previous studies reported that 4-1BB-based CD19 chimeric antigen receptor(CAR)-T cells were more beneficial for the clinical outcomes than CD28-based CAR-T cells,especially the lower incidence rate of severe adverse ***,the median progression-free survival(mPFS)of 4-1BB-based product Kymriah was shorter than that of CD28-based Yescarta(2.9 months vs.5.9 months),suggesting that Kymriah was limited in the long-term ***,a safe and durable 4-1BB-based CD19 CAR-T needs to be ***:We designed a CD19-targeted CAR-T(named as IM19)which consisted of an FMC63 scFv,4-1BB and CD3ζintracellular domain and was manufactured into a memory T-enriched formulation.A phase I/II clinical trial was launched to evaluate the clinical outcomes of IM19 in relapsed or refractory(r/r)B cell non-Hodgkin lymphoma(B-NHL).Dose-escalation investigation(at a dose of 5×10^(5)/kg,1×10^(6)/kg and 3×106/kg)was performed in 22 r/r B-NHL *** patients received a single infusion of IM19 after 3-day conditional ***:At month 3,the overall response rate(ORR)was 59.1%,the complete response rate(CRR)was 50.0%.The mPFS was 6 months and the 1-year overall survival rate was 77.8%.Cytokine release syndrome(CRS)occurred in 13 patients(59.1%),with 54.5%of grade 1−2 *** one patient(4.5%)experienced grade 3 CRS and grade 3 ***:These results demonstrated the safety and durable efficacy of a 4-1BB-based CD19 CAR-T,IM19,which is promising for further development and clinical investigation.

关键词： CD19 CAR-T 4-1BB safety durable efficacy

Prognostic value of interim ^(18)F-FDG PET/CT in diffuse large B-cell lymphoma

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2013年第1期25卷 95-101页

作者： Zhitao Ying Xuejuan Wang Yuqin Song Wen Zheng Xiaopei Wang Yan Xie ningjing lin Meifeng Tu lingyan Ping Weiping Liu Lijuan Deng Chen Zhang Zhi Yang Jun Zhu Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) Department of LymphomaPeking University Cancer Hospital & Institute Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) Department of Nuclear MedicinePeking University Cancer Hospital & Institute

Objective： Diffuse large B-cell lymphoma （DLBCL） is a heterogeneous disease. The prognostic factor currently used is not accurate enough to predict the outcomes of patients with DLBCL. The prognostic significance of interim PET/CT in DLBCL remains controversial. The aim of this study is to determine the predictive value of interim 18F-FDG PET/CT after first-line treatment in patients with DLBCL. Methods： Thirty-two patients with DLBCL underwent baseline, interim and post-treatment lSF-FDG PET/CT scans. Imaging results were analyzed for the survival of patients via software SPSS 13.0, retrospectively. Results： Thirty-one of the 32 patients were treated with R-CHOP regimen, and interim 18F-FDG PET/CT of 24 patients was performed after 2 cycles of treatment. After a median follow-up period of 16.7 months, the 2-year progression-free survival （PFS） rates were significantly different between the groups above and below SUVmax CUt-Off value of 2.5 （P=0.039）. No significant differences were found in the 2-year PFS rates if SUVm, cut-offvalues were set as 2.0 and 3.0, respectively （P=0.360; P=0.113）. Conclusions： Interim PET/CT could predict the prognosis of DLBCL patients with the SUVmax cut-off value of 2.5, but more clinical data should be concluded to confirm this conclusion.

关键词： Fludeoxy-glucose F18 lyrnphoma large cell diffuse prognosis standard utility value

^18F-FDG PET/CT对原发性甲状腺淋巴瘤疗效及预后的评估

在线全文

学校读者我要写书评

暂无评论

中国医学影像学杂志 2016年第3期24卷 161-165页

作者：范洋林宁晶杨志应志涛朱军王雪鹃北京大学肿瘤医院暨北京市肿瘤防治研究所核医学科恶性肿瘤发病机制及转化研究教育部重点实验室北京100142 北京大学肿瘤医院暨北京市肿瘤防治研究所淋巴肿瘤科恶性肿瘤发病机制及转化研究教育部重点实验室北京100142

目的原发性甲状腺淋巴瘤(PTL)是极为罕见的恶性肿瘤,本研究通过分析PTL的形态及代谢特征,探讨^(18)F-FDG PET/CT在PTL疗效及预后评估中的应用价值。资料与方法回顾性分析行^(18)F-FDG PET/CT扫描的1101例淋巴瘤患者,其中16例诊断为PTL,... 详细信息

目的原发性甲状腺淋巴瘤(PTL)是极为罕见的恶性肿瘤,本研究通过分析PTL的形态及代谢特征,探讨^(18)F-FDG PET/CT在PTL疗效及预后评估中的应用价值。资料与方法回顾性分析行^(18)F-FDG PET/CT扫描的1101例淋巴瘤患者,其中16例诊断为PTL,分析治疗前PET/CT图像特点,利用中期PET/CT评估11例PTL患者的疗效,应用五分法及SUVmax减少率(%ΔSUVmax)法判读图像,构建生存曲线,评估无进展生存时间(PFS)及总生存时间(OS)。结果治疗前PTL病灶特征性地表现为甲状腺内高代谢结节或双叶弥漫性肿大伴高代谢,伴或不伴高代谢淋巴结。治疗前SUVmax值不能判定预后(P>0.05)。11例患者行中期PET/CT检查,其中8例对治疗完全反应,2例部分反应,1例死亡;1例无反应而死亡。五分法评估中期^(18)F-FDG PET/CT图像优于%ΔSUVmax法;PET阴性患者3年PFS及OS值均为100.0%,PET阳性患者为(33.3±27.2)%,差异有统计学意义(P<0.05)。结论 ^(18)F-FDG PET/CT能灵敏地检测出PTL病灶,准确分期,并能初步评估疗效及预后。

关键词：甲状腺肿瘤淋巴瘤正电子发射断层显像术体层摄影术,X线计算机氟脱氧葡萄糖F18 治疗结果预后

超声图像纹理分析在乳腺BI-RADS 3类或4a类结节中的临床价值

在线全文

学校读者我要写书评

暂无评论

中国超声医学杂志 2022年第3期38卷 271-273页

作者：农万贤唐小珍林宁静刘慧宇高泳广西医科大学第一附属医院超声科

目的探讨超声图像纹理分析对乳腺BI-RADS 3类或4a类结节良恶性病变的鉴别诊断价值。方法回顾性分析乳腺常规超声评估为BI-RADS 3类或4a类的患者224例，将良性及恶性病例分为训练集和测试集，勾取感兴趣区，提取纹理特征，基于训练集... 详细信息

目的探讨超声图像纹理分析对乳腺BI-RADS 3类或4a类结节良恶性病变的鉴别诊断价值。方法回顾性分析乳腺常规超声评估为BI-RADS 3类或4a类的患者224例，将良性及恶性病例分为训练集和测试集，勾取感兴趣区，提取纹理特征，基于训练集采用套索回归及交叉验证进行特征筛选和建模，采用ROC曲线评估模型诊断效能。结果共提取279个纹理特征，经套索回归及交叉验证筛选出11个特征，构建的超声组学评分模型在训练集和测试集的曲线下面积、灵敏度和特异度分别为0.818、0.789、0.747; 0.837、0.829、0.724。结论超声组学评分模型对乳腺BI-RADS 3类或4a类结节中的良恶性病变具有良好的鉴别诊断效能。

关键词：纹理分析超声组学超声检查乳腺结节